We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Unique Diagnostic Test Based on Mass Spectrometry Technique Accurately Identifies Early-Stage Alzheimer's Disease

By LabMedica International staff writers
Posted on 16 Mar 2022
Print article
Image: New assay enables simultaneous determination of total Aβ40 and Aβ42 levels (Photo courtesy of Araclon Biotech)
Image: New assay enables simultaneous determination of total Aβ40 and Aβ42 levels (Photo courtesy of Araclon Biotech)

Cerebral amyloid load is one of the first signs of early-onset Alzheimer's Disease (AD) in individuals with subjective memory complaints (SMCs) and has potential for use as a biomarker to indicate how the condition evolves. A new assay based on mass spectrometry has shown to be capable of quantifying amyloid-beta 40 and 42 proteins – both associated with the risk of having AD – in plasma samples.

Araclon Biotech (Zaragoza, Spain), a Grifols Group company, has developed ABtest-MS, a novel and unique method based on the mass spectrometry technique, that is capable of accurately quantifying amyloid 40 and 42 proteins in plasma samples. Diverse studies have confirmed the high predictive ability of the ABtest-MS assay to identify precisely those subjects with cerebral amyloid load, which would enable management of AD in its initial phases. ABtest-MS is a differentiating method that does not contain antibodies and whose process avoids enzymatic digestion, saving time and expense.

Data from the trial conducted on the FACEHBI cohort, obtained after two years of follow up, confirm the potential of the ABtest-MS to predict cerebral amyloid load in individuals with SMCs and the potential that the analysis of these markers have as an indicator of how the condition evolves. The data corresponding to five years of follow up with the cohort are currently being analyzed. In the second study, the multicenter A4 Study carried out in 50 centers, the ABtest-MS predicted the cerebral deposit of the amyloid protein (measured by PET) in plasma samples from 731 subjects. It also confirmed the suitability of utilizing a centralized and extensively validated method such as this assay in these broad and heterogenous studies. These data confirm other results previously obtained on more than 1,000 subjects in different AD stages from various international cohorts that have been recently featured in scientific publications.

"This test's predictive ability makes it ideal to detect early-stage Alzheimer's and accelerate the recruitment for clinical trials of new treatments, reducing the screening failure rate and associated costs," said Jose Terencio, Araclon CEO and Vice President of Innovation at Grifols.

Related Links:
Araclon Biotech 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.